- Home
- SB vs GHRS Comparison
SB vs GHRS Comparison
Compare SB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- GHRS
- Stock Information
- Founded
- SB 2007
- GHRS 2018
- Country
- SB Monaco
- GHRS Ireland
- Employees
- SB N/A
- GHRS N/A
- Industry
- SB Marine Transportation
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- SB Consumer Discretionary
- GHRS Health Care
- Exchange
- SB Nasdaq
- GHRS Nasdaq
- Market Cap
- SB 374.8M
- GHRS 402.7M
- IPO Year
- SB 2008
- GHRS 2021
- Fundamental
- Price
- SB $3.50
- GHRS $6.85
- Analyst Decision
- SB Strong Buy
- GHRS Strong Buy
- Analyst Count
- SB 1
- GHRS 3
- Target Price
- SB $6.00
- GHRS $35.67
- AVG Volume (30 Days)
- SB 826.3K
- GHRS 58.0K
- Earning Date
- SB 02-10-2025
- GHRS 11-14-2024
- Dividend Yield
- SB 5.70%
- GHRS N/A
- EPS Growth
- SB 35.10
- GHRS N/A
- EPS
- SB 0.90
- GHRS N/A
- Revenue
- SB $318,430,000.00
- GHRS N/A
- Revenue This Year
- SB $6.67
- GHRS N/A
- Revenue Next Year
- SB N/A
- GHRS N/A
- P/E Ratio
- SB $3.91
- GHRS N/A
- Revenue Growth
- SB 10.27
- GHRS N/A
- 52 Week Low
- SB $3.40
- GHRS $5.08
- 52 Week High
- SB $6.33
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- SB 27.21
- GHRS 35.35
- Support Level
- SB $3.40
- GHRS $7.20
- Resistance Level
- SB $3.69
- GHRS $8.91
- Average True Range (ATR)
- SB 0.15
- GHRS 0.86
- MACD
- SB -0.02
- GHRS -0.18
- Stochastic Oscillator
- SB 14.71
- GHRS 3.96
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.